 | |
| Clinical data | |
|---|---|
| Other names | N-Allylnorcodeine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H23NO3 |
| Molar mass | 325.408 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nalodeine, also known more commonly asN-allylnorcodeine, is anopioid antagonist (specifically, anantagonist of theμ-opioid receptor) that was never marketed but is notable as the first opioid antagonist to be discovered.[1][2] It was first reported in 1915 and was found to block the effects ofmorphine in animals.[3][2] This was followed by the clinical introduction ofnalorphine (N-allylnormorphine) in 1954,naloxone (N-allyloxymorphone) in 1960, andnaltrexone (N-methylcyclopropyloxymorphone) in 1963.[2]Nalmefene (6-desoxy-6-methylene-naltrexone), another structurally related opioid antagonist derivative, was also subsequently introduced, in 1996.[4] In animals, nalodeine both reversesmorphine- andheroin-inducedrespiratory depression and acts as arespiratory stimulant in its own right (i.e., when given alone).[5] Similarly to nalorphine, nalodeine has also been found to act as anagonist of theκ-opioid receptor.[6]
